Merck Presents New Analyses Supporting the Promising Potential of ...

New analyses from studies of sotatercept, Merck's novel investigational activin signaling inhibitor biologic, for adults with pulmonary arterial hypertension ( ...

Merck, known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck' s novel ...

Merck Presents New Analyses Supporting the Promising Potential of ...

A new exploratory post-hoc analysis of right heart catheterization and echocardiography data from patients in the Phase 3 STELLAR study showed ...

Merck to Present Survival Data and New Research on 10 ...

Presentations at the Congress will feature new or updated findings from Merck's broad portfolio of cancer medicines: KEYTRUDA ® (pembrolizumab), ...

New STELLAR, SOTERIA Data Provide Insight into Effects of ...

Merck presents new analyses supporting the promising potential of SOTATERCEPT, its investigational medicine for adults with pulmonary ...

Merck Announces Third-Quarter 2023 Financial Results

The company is initiating Phase 3 trials in 2023 in multiple therapeutic areas, including oncology, cardiometabolic and immunology, and in new ...

Ifinatamab Deruxtecan Continues to Demonstrate Promising ...

Merck will be solely responsible for manufacturing and supply for MK-6070. About the ADC Portfolio of Daiichi Sankyo. The Daiichi Sankyo ADC ...

Merck & Co. | DAIC - Diagnostic and Interventional Cardiology

September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck's novel investigational activin ... Home September 12, 2023. arrow · As ...

Merck to Present New Data for Sotatercept and MK-0616 at ACC.23 ...

Merck acquired exclusive rights to sotatercept in the pulmonary hypertension field through the acquisition of Acceleron Pharma Inc. Sotatercept ...

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational ...

“Based on early evidence showing MK-1084 in combination with KEYTRUDA had a manageable safety profile and promising anti-tumor activity, we are ...

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 ...

“We believe that our mRNA technology has the potential to improve the outcomes of those affected by lung cancer and together, INTerpath-002 and ...

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study ...

Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories. “By combining ...

Frespaciguat - Drug Targets, Indications, Patents - Patsnap Synapse

FDA approval of a new Merck drug marks the first for a therapy addressing an underlying cause of the disease. The Tuesday approval of the Merck drug covers the ...

Merck to Present New Data at ASCO 2024

Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at ...

Moderna, Merck Present Promising Trial Data for a Combination of ...

"We are encouraged by the latest results from the KEYNOTE-942/mRNA-4157-P201 study. These data highlight the sustained benefit in RFS and ...

Merck, KGaA, Darmstadt, Germany, to Present New Data - EMD Group

“In addition, new analyses from pivotal studies and collaborations underline our determination to maximize the impact of our standard-of-care ...

Merck to Present Extensive New Research Demonstrating ...

Presentations will feature new or updated findings from Merck's broad portfolio of cancer medicines: KEYTRUDA, Merck's anti-PD-1 therapy; ...

Merck posts fresh sotatercept data ahead of FDA approval ruling

This is encouraging and further supports the primary results from the STELLAR analysis, underscoring the potential of sotatercept to play a ...

Merck's $11.5 Billion Bet on Its Next Big Drug Finally Arrives - WSJ

Merck is counting on the blockbuster performance. More than 40% of the drug company's revenue, some $25 billion last year, comes from cancer ...

Merck to Present Latest Research from Oncology Portfolio at ESMO

At Merck, we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising ...